264 related articles for article (PubMed ID: 8479736)
41. COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer.
Raspollini MR; Amunni G; Villanucci A; Boddi V; Taddei GL
Acta Obstet Gynecol Scand; 2006; 85(4):493-8. PubMed ID: 16612714
[TBL] [Abstract][Full Text] [Related]
42. Second-look laparotomy for ovarian cancer provides reliable prognostic information and improves survival.
Friedman RL; Eisenkop SM; Wang HJ
Gynecol Oncol; 1997 Oct; 67(1):88-94. PubMed ID: 9345362
[TBL] [Abstract][Full Text] [Related]
43. Preoperative predictors for residual tumor after surgery in patients with ovarian carcinoma.
de Jong D; Eijkemans MJ; Lie Fong S; Gerestein CG; Kooi GS; Baalbergen A; van der Burg ME; Burger CW; Ansink AC
Oncology; 2007; 72(5-6):293-301. PubMed ID: 18198490
[TBL] [Abstract][Full Text] [Related]
44. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study.
Paramasivam S; Tripcony L; Crandon A; Quinn M; Hammond I; Marsden D; Proietto A; Davy M; Carter J; Nicklin J; Perrin L; Obermair A
J Clin Oncol; 2005 Sep; 23(25):5938-42. PubMed ID: 16087942
[TBL] [Abstract][Full Text] [Related]
45. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
[TBL] [Abstract][Full Text] [Related]
46. TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms.
Harłozinska A; Sedlaczek P; Van Dalen A; Rozdolski K; Einarsson R
Anticancer Res; 1997; 17(6D):4473-8. PubMed ID: 9494553
[TBL] [Abstract][Full Text] [Related]
47. [Prognostic value of CA 125 initial half-life measured during first-line chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV].
Riedinger JM; Barillot I; Coudert B; Fargeot P; Berriolo-Riedinger A; Guerrin J
Bull Cancer; 1996 Aug; 83(8):654-63. PubMed ID: 8869046
[TBL] [Abstract][Full Text] [Related]
48. Correlation of platelet count with second-look laparotomy results and disease progression in patients with advanced epithelial ovarian cancer.
Bozkurt N; Yuce K; Basaran M; Kose F; Ayhan A
Obstet Gynecol; 2004 Jan; 103(1):82-5. PubMed ID: 14704249
[TBL] [Abstract][Full Text] [Related]
49. Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction.
Mahner S; Woelber L; Jung S; Eulenburg CZ; Ihnen M; Schwarz J; Sehouli J; Jaenicke F
Anticancer Res; 2009 Jul; 29(7):2817-21. PubMed ID: 19596967
[TBL] [Abstract][Full Text] [Related]
50. CA 125 in monitoring chemotherapy of patients with ovarian cancer: early response to the treatment.
Markowska J; Kopczyński Z; Manyś G; Szewierski Z
Neoplasma; 1990; 37(6):687-92. PubMed ID: 2274087
[TBL] [Abstract][Full Text] [Related]
51. [The role of tumor marker CA 125 in the treatment of ovarian cancer].
Porsbjerg CM; Sørensen JB; Lund BA
Ugeskr Laeger; 1998 Feb; 160(7):995-1000. PubMed ID: 9477746
[TBL] [Abstract][Full Text] [Related]
52. [Experiences with the tumor markers Ca 125 and plasma ribonuclease in ovarian cancer].
Lücke R; Benz R; Kraus H
Geburtshilfe Frauenheilkd; 1987 Dec; 47(12):846-9. PubMed ID: 3481339
[TBL] [Abstract][Full Text] [Related]
53. Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma.
Geisler JP; Miller GA; Lee TH; Harwood RM; Wiemann MC; Geisler HE
J Reprod Med; 1996 Mar; 41(3):140-2. PubMed ID: 8778409
[TBL] [Abstract][Full Text] [Related]
54. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
55. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.
Chi DS; Venkatraman ES; Masson V; Hoskins WJ
Gynecol Oncol; 2000 May; 77(2):227-31. PubMed ID: 10785469
[TBL] [Abstract][Full Text] [Related]
56. Preoperative value of CA 125 as a reflection of tumor grade in epithelial ovarian cancer.
But I; Gorisek B
Gynecol Oncol; 1996 Nov; 63(2):166-72. PubMed ID: 8910622
[TBL] [Abstract][Full Text] [Related]
57. Is there a role for second-look laparotomy in the management of malignant germ cell tumors of the ovary? Experience at Institut Gustave Roussy.
Culine S; Lhomme C; Michel G; Leclere J; Duvillard P; Droz JP
J Surg Oncol; 1996 May; 62(1):40-5. PubMed ID: 8618400
[TBL] [Abstract][Full Text] [Related]
58. [Predictive value of a tumor marker combination for the monitoring of ovarian cancer].
Lahousen M
Wien Klin Wochenschr; 1986 May; 98(10):319-25. PubMed ID: 3460273
[TBL] [Abstract][Full Text] [Related]
59. Factors associated with cytoreducibility among women with ovarian carcinoma.
Eltabbakh GH; Mount SL; Beatty B; Simmons-Arnold L; Cooper K; Morgan A
Gynecol Oncol; 2004 Nov; 95(2):377-83. PubMed ID: 15491760
[TBL] [Abstract][Full Text] [Related]
60. Monoclonal antibodies MA54 and MA61 as potential reagents in the prognosis of patients with ovarian cancer.
Kobayashi H; Ohi H; Sugimura M; Shinohara H; Terao T
Gynecol Oncol; 1993 Apr; 49(1):80-5. PubMed ID: 8482565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]